Open Beta
TREN
MetriLume
TREN

US marketsPTHS

SEC-sourced researchBeta

PTHS

Pelthos Therapeutics Inc.

Company comparison ↗

Data passport

CIK
0001919246
Exchange
NYSE
Business activity
— · SIC 2836
Financial inputs
6/6
Filing date
Oct 1, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 0.0000 USD; December 2025: 16,795,000.0000 USD16.8M USD0 USD0December 2024December 2025
PTHS · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20240.0000Mar 19, 2026
December 202516,795,000.0000Mar 19, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202516,795,000.0000-43,319,000.0000-22,590,000.0000130,397,000.000091,516,000.0000Mar 19, 2026
December 20240.0000-7,955,000.0000-5,792,000.00001,369,000.00004,083,000.0000Mar 19, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$16.8MDecember 2025Mar 19, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$0December 2024Mar 19, 202610-K
Net incomeNetIncomeLoss-$43.32MDecember 2025Mar 19, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$22.59MDecember 2025Mar 19, 202610-K
Total assetsAssets$130.4MDecember 2025Mar 19, 202610-K
Total liabilitiesLiabilities$91.52MDecember 2025Mar 19, 202610-K

New filings

Explore methodology ↗